Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects.

Mayo PR, Huizinga RB, Ling SY, Freitag DG, Aspeslet LJ, Foster RT.

J Clin Pharmacol. 2013 Aug;53(8):819-26. doi: 10.1002/jcph.114. Epub 2013 Jun 4.

PMID:
23736966
2.

Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.

Guo B, Wu X, Zhang Y, Shi Y, Yu J, Cao G, Zhang J.

Clin Drug Investig. 2012 Jul 1;32(7):475-86. doi: 10.2165/11632780-000000000-00000.

PMID:
22650326
3.

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.

Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.

Clin Ther. 2008 Oct;30(10):1817-30. doi: 10.1016/j.clinthera.2008.10.013.

PMID:
19014837
4.

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.

Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F.

Br J Clin Pharmacol. 2013 Feb;75(2):476-87. doi: 10.1111/j.1365-2125.2012.04369.x.

6.

Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.

Derks M, Kawamura H, Abt M, Meneses-Lorente G, Phelan M, Ishikawa T.

Clin Ther. 2011 Jun;33(6):754-65. doi: 10.1016/j.clinthera.2011.05.046.

PMID:
21704240
7.

Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.

Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT.

Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309.

8.

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.

Clin Ther. 2009 Oct;31(10):2258-71. doi: 10.1016/j.clinthera.2009.10.019.

PMID:
19922897
9.

Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers.

Lu C, Jia Y, Chen L, Ding Y, Yang J, Chen M, Song Y, Sun X, Wen A.

J Clin Pharm Ther. 2013 Apr;38(2):136-40. doi: 10.1111/jcpt.12023. Epub 2012 Dec 28.

PMID:
23278367
10.
11.
12.

Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.

Kim TE, Lim KS, Park MK, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.

Clin Ther. 2012 Sep;34(9):1986-98. doi: 10.1016/j.clinthera.2012.08.006. Epub 2012 Sep 1.

PMID:
22943970
13.

Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity.

Chen N, Kasserra C, Reyes J, Liu L, Lau H.

Cancer Chemother Pharmacol. 2012 Nov;70(5):717-25. doi: 10.1007/s00280-012-1966-z. Epub 2012 Sep 6.

PMID:
22955172
14.

Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.

Namour F, Vanhoutte FP, Beetens J, Blockhuys S, De Weer M, Wigerinck P.

Drugs R D. 2012 Sep 1;12(3):141-63. doi: 10.2165/11633120-000000000-00000.

15.

Pharmacokinetics of voclosporin in renal impairment and hepatic impairment.

Ling SY, Huizinga RB, Mayo PR, Freitag DG, Aspeslet LJ, Foster RT.

J Clin Pharmacol. 2013 Dec;53(12):1303-12. doi: 10.1002/jcph.166. Epub 2013 Oct 8.

PMID:
23996158
16.

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D.

Cancer Chemother Pharmacol. 2012 Jan;69(1):221-7. doi: 10.1007/s00280-011-1688-7. Epub 2011 Jun 21.

PMID:
21691746
17.

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, Van Hoydonck P, Laethem T, Van Dyck K, Chen J, Chavez-Eng C, Archer L, Lutz R, Hilliard D, Snyder K, Jin B, Van Bortel L, Lasseter KC, Al-Huniti N, Dykstra K, Gottesdiener K, Wagner JA.

Br J Clin Pharmacol. 2009 Oct;68(4):535-45. doi: 10.1111/j.1365-2125.2009.03465.x.

18.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.

Chi YH, Lee H, Paik SH, Lee JH, Yoo BW, Kim JH, Tan HK, Kim SL.

Am J Cardiovasc Drugs. 2011 Oct 1;11(5):335-46. doi: 10.2165/11593840-000000000-00000.

PMID:
21910510
19.

Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.

Cox DS, Papadopoulos K, Fang L, Bauman J, LoRusso P, Tolcher A, Patnaik A, Pendry C, Orford K, Ouellet D.

J Clin Pharmacol. 2013 Sep;53(9):946-54. doi: 10.1002/jcph.115. Epub 2013 Jul 25.

PMID:
23893461
20.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580

Supplemental Content

Support Center